Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors
Open Access
- 13 December 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 107 (6) , 1081-1095
Abstract
Epithelial ovarian cancer displays the highest mortality of all gynecological tumors. A relapse of the disease even after successful surgical treatment is a significant problem. Resistance against the current platinum‐based chemotherapeutic standard regime requires a detailed ex vivo immune profiling of tumor‐infiltrating cells and the development of new therapeutic strategies. In this study, we phenotypically and functionally characterize tumor cells and autologous tumor‐derived αβ and γδ T lymphocyte subsets. Tumor‐infiltrating (TIL) and tumor‐ascites lymphocytes (TAL) were ex vivo isolated out of tumor tissue and ascites, respectively, from high‐grade ovarian carcinoma patients (FIGO‐stage IIIa‐IV). We observed an increased γδ T cell percentage in ascites compared to tumor‐tissue and blood of these patients, whereas CD8+ αβ T cells were increased within TAL and TIL. The number of Vδ1 and non‐Vδ1/Vδ2‐expressing γδ T cells was increased in the ascites and in the tumor tissue compared to the blood of the same donors. Commonly in PBL, the Vγ9 chain of the γδ T cell receptor is usually associated exclusively with the Vδ2 chain. Interestingly, we detected Vδ1 and non‐Vδ1/Vδ2 T cells co‐expressing Vγ9, which is so far not described for TAL and TIL. Importantly, our data demonstrated an expression of human epidermal growth factor receptor (HER)‐2 on high‐grade ovarian tumors, which can serve as an efficient tumor antigen to target CD3 TIL or selectively Vγ9‐expressing γδ T cells by bispecific antibodies (bsAbs) to ovarian cancer cells. Our bsAbs efficiently enhance cytotoxicity of TIL and TAL against autologous HER‐2‐expressing ovarian cells.Keywords
Funding Information
- DFG (WE 3559/6-1—FOR2799)
- Deutsche Krebshilfe Mildred-Scheel professorship program
- California Department of Fish and Game (WE 3559/6‐1—FOR2799)
This publication has 48 references indexed in Scilit:
- Identification of Ovarian Cancer Metastatic miRNAsPLOS ONE, 2013
- Pertuzumab: new hope for patients with HER2-positive breast cancerAnnals of Oncology, 2012
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 PatientsPLOS ONE, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- HER-2/neuoverexpression in uterine papillary serous cancers and its possible therapeutic implicationsInternational Journal of Gynecological Cancer, 2006
- Use of trastuzumab in the treatment of metastatic endometrial cancerInternational Journal of Gynecological Cancer, 2006
- Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor CellsJournal of Experimental Medicine, 2003
- Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activationNature, 2002
- Chemical Synthesis and Biological Activity of Bromohydrin Pyrophosphate, a Potent Stimulator of Human γδ T CellsJournal of Biological Chemistry, 2001